15-Year watch begins for gene therapy recipients
NCT ID NCT06882317
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 31 times
Summary
This study follows 40 people who have already received CLBR001, a gene therapy that uses a lentivirus to deliver a chimeric antigen receptor. Researchers will monitor participants for 15 years to detect any delayed side effects or safety issues. The goal is to understand the long-term risks of this type of gene therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG-TERM FOLLOW-UP are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Virtual Research Group- Premier Research
Morrisville, North Carolina, 27560, United States
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.